We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

62 hedge funds and large institutions have $397M invested in Entrada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

13% more funds holding

Funds holding: 55 → 62 (+7)

0.65% more ownership

Funds ownership: 78.26% → 78.91% (+0.65%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

3% less capital invested

Capital invested by funds: $411M → $397M (-$14M)

Holders
62
Holders Change
+7
Holders Change %
+12.73%
% of All Funds
0.9%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
10
Increased
22
Reduced
14
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AACP
Advantage Alpha Capital Partners
California
+$1.56M
2
American Century Companies
American Century Companies
Missouri
+$1.48M
3
BlackRock
BlackRock
New York
+$1.45M
4
Morgan Stanley
Morgan Stanley
New York
+$1.15M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$713K

Top Sellers

1
7IH
72 Investment Holdings
Connecticut
-$4.98M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$690K
3
CIC
Cornercap Investment Counsel
Georgia
-$221K
4
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$158K
5
Northern Trust
Northern Trust
Illinois
-$64.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$73.4M – – –
MAM
2
MPM Asset Management
Massachusetts
$66.8M – – –
5VM
3
5AM Venture Management
California
$66.5M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$45.4M +$143K +9,636 +0.3%
BlackRock
5
BlackRock
New York
$22.7M +$1.45M +98,134 +7%
RG
6
Redmile Group
California
$19.4M -$3.93K -265 -0%
Vanguard Group
7
Vanguard Group
Pennsylvania
$16.1M +$664K +44,849 +4%
Wellington Management Group
8
Wellington Management Group
Massachusetts
$15.8M +$31.5K +2,128 +0.2%
SG
9
StepStone Group
California
$11.5M – – –
TCM
10
TCG Crossover Management
California
$8.83M – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$8.08M -$690K -46,593 -8%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$6.93M +$308K +20,800 +5%
State Street
13
State Street
Massachusetts
$6.46M +$364K +24,579 +6%
American Century Companies
14
American Century Companies
Missouri
$3.6M +$1.48M +99,847 +72%
Northern Trust
15
Northern Trust
Illinois
$3.03M -$64.8K -4,373 -2%
7IH
16
72 Investment Holdings
Connecticut
$2.6M -$4.98M -336,423 -66%
Charles Schwab
17
Charles Schwab
California
$2.28M -$57.3K -3,866 -2%
TD Asset Management
18
TD Asset Management
Ontario, Canada
$1.8M – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.74M +$713K +48,107 +72%
AACP
20
Advantage Alpha Capital Partners
California
$1.59M +$1.56M +105,137 New
MCM
21
Moore Capital Management
New York
$1.58M – – –
Morgan Stanley
22
Morgan Stanley
New York
$1.49M +$1.15M +77,662 +371%
N
23
Nuveen
North Carolina
$1.21M +$106K +7,148 +10%
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$840K -$7.02K -474 -0.8%
NFGH
25
Nan Fung Group Holdings
Hong Kong
$741K – – –
1
2 3

TRDA Hedge Fund Activity: Q4 2023 in Review

62 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2023, worth a combined $397M — down 3.4% from $411M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TRDA positions and 3 closed out — a net gain of 7 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Advantage Alpha Capital Partners, opening a new position worth an estimated $1.56M. The largest seller was 72 Investment Holdings, cutting an estimated $4.98M.

  • 62 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2023, up from 55 in Q3 2023.
  • Funds reported $397M of Entrada Therapeutics stock for Q4 2023, down 3.4% quarter-over-quarter.
  • 10 funds opened new Entrada Therapeutics positions in Q4 2023 and 3 closed out, a net change of +7 holders.
  • The largest Entrada Therapeutics buyer in Q4 2023 was Advantage Alpha Capital Partners, an estimated $1.56M added.
  • The largest Entrada Therapeutics seller in Q4 2023 was 72 Investment Holdings, an estimated $4.98M sold.

Based on aggregated 13F filings for Q4 2023.